Rubitecan

Rubitecan
Clinical data
Trade names	Orathecin
Other names	9-Nitrocamptothecin; 9-NC; 9-Nitro-20(S)-camptothecin; Camptogen; (19S)-19-Ethyl-19-hydroxy-10-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa- 1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione;
Routes of; administration	Oral (capsules)
ATC code	None;
Legal status
Legal status	Application withdrawn;
Pharmacokinetic data
Bioavailability	25–30% (rubitecan and 9-AC; in dogs)
Protein binding	97% (rubitecan), 65% (9-AC)
Metabolism	Probably CYP-dependent
Metabolites	9-Aminocamptothecin (9-AC)
Elimination half-life	15–18 hours (rubitecan), 18–22 hours (9-AC)
Excretion	Bile and feces (major proportion), urine (the minor one)
Identifiers
	IUPAC name (4S)-4-Ethyl-4-hydroxy-11-nitro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione;
CAS Number	91421-42-0 ;
PubChem CID	472335;
ChemSpider	414807 ;
UNII	H19C446XXB;
KEGG	D04031 ;
ChEBI	CHEBI:90225 ;
ChEMBL	ChEMBL77305 ;
CompTox Dashboard (EPA)	DTXSID7046752 ;
Chemical and physical data
Formula	C20H15N3O6
Molar mass	393.355 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=C(C=CC=C5[N+](=O)[O-])N=C4C3=C2)O;
	InChI InChI=1S/C20H15N3O6/c1-2-20(26)13-7-16-17-10(8-22(16)18(24)12(13)9-29-19(20)25)6-11-14(21-17)4-3-5-15(11)23(27)28/h3-7,26H,2,8-9H2,1H3/t20-/m0/s1 ; Key:VHXNKPBCCMUMSW-FQEVSTJZSA-N ;
	(what is this?) (verify)

Rubitecan (INN, trade name Orathecin) is an oral topoisomerase inhibitor, developed by SuperGen (now Astex Pharmaceuticals, a member of the Otsuka Group).